Baxter International’s share price has fallen sharply over the past few years, yet valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach currently point to the stock trading at a discount to its underlying cash flow outlook.

• Over the past 5 years, Baxter International’s share price has declined 70.7%, which puts recent gains into the context of a long and steep drawdown that investors are still weighing against the current valuation.
• The new multi-year distribution partnership to roll out the SHIYA 3D surgical visualization platform may support longer term growth expectations. At the same time, concerns that the company could still prove to be a value trap highlight ongoing risk around execution and capital allocation.
• Baxter International screens as undervalued on most of Simply Wall St’s checks, with the company passing 5 of 6 broader valuation tests. This suggests the overall framework leans cheap rather than expensive for the current share price.

The issue now is whether Baxter International’s recent share price recovery is enough to close the gap to its intrinsic value estimate, or if the discount still compensates for the risks around its turnaround story.

Is Baxter International a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model used here is based on projected cash flows to equity over two stages. For Baxter International, the latest twelve month free cash flow is about $751 million, with the model treating future cash flows as recovering rather than contracting. On these projections, the DCF points to an estimated intrinsic value of about $28.82 per share.

Compared with the current share price, that implies Baxter International trades at roughly a 24.7% discount, so the stock screens as undervalued on this cash flow view. The recent multi year SHIYA 3D distribution agreement helps explain why some investors may see the current gap between price and intrinsic value as reflecting execution risk rather than a weak cash flow base.

On balance, the DCF output suggests Baxter International stock appears undervalued relative to the cash flows currently built into the model.

Our Discounted Cash Flow (DCF) analysis suggests Baxter International is undervalued by 24.7%. Track this in your watchlist or portfolio, or discover 41 more high quality undervalued stocks.

Is Baxter International Still Cheap on Sales?

P/S is often a useful yardstick for Baxter International because revenue is a key reference point for many medical equipment companies. Baxter International currently trades at a P/S of about 1.0x, compared with an industry average of roughly 2.7x and a broader peer group around 7.2x, so the stock sits well below both benchmarks on this metric.

The fair P/S ratio, which adjusts for factors like the company’s margins, risk profile and size, is estimated at about 1.3x. That is still above the current level, and this indicates the market is pricing Baxter International at a discount even after accounting for those business characteristics. When this is considered alongside the DCF work, the low P/S suggests investors are still applying a cautious view to the revenue base.

On balance, Baxter International appears undervalued on the P/S multiple compared with both its tailored fair ratio and sector peers.

The Baxter International Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Baxter International take the valuation puzzle a step further by spelling out which assumptions about Baxter International's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, and they sit on the Community page. Each narrative ties a specific fair value to a clear story about Baxter International's potential catalysts and risks, so you can track over time which version of events appears to be unfolding.

The Baxter International community is split between a turnaround story with margin recovery and a more cautious view that sees structural pressures keeping a lid on the stock.

Bull case: 35% undervalued

"Baxter's streamlined post-divestiture structure, coupled with the incoming CEO's aggressive operational track record and focus on innovation, sets the company up for transformation, unlocking cost reductions and margin expansion beyond current expectations as new leadership realigns resources for high-growth areas…"

Bear case: 28% overvalued

"Accelerating adoption of preventive care and at-home digital health solutions is reducing demand for traditional hospital-based therapies, which underpin a major share of Baxter's product portfolio; this sustained shift will erode the addressable market for Baxter's IV solutions, infusion pumps and hospital-focused therapies, undermining both top-line revenue and earnings growth…"

Do you think there's more to the story for Baxter International? Head over to our Community to see what others are saying!

The Bottom Line

Baxter International screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and on sales based multiples, which broadly point in the same direction. The key question is whether that discount reflects mispricing or is a fair response to the execution and capital allocation risks that still hang over the turnaround. From here, the crux of the Baxter International debate is whether management can translate the current product pipeline and portfolio reshaping into durable margin and cash flow improvement, or whether the stock remains a potential value trap despite the apparent valuation gap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.